Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)
Authors:
- David Patrick KateeteDKDavid Patrick Kateete
- Rogers KamulegeyaRKRogers Kamulegeya
- Edgar KigoziEKEdgar Kigozi
- Fred Ashaba KatabaziFKFred Ashaba Katabazi
- Deus LukoyeDLDeus Lukoye
- Sindani Ireneaus SebitSSSindani Ireneaus Sebit
- Hergeye AbdiHAHergeye Abdi
- Peter ArubePAPeter Arube
- George William KasuleGKGeorge William Kasule
- Kenneth MusisiKMKenneth Musisi
- Myalo Glen DlaminiMDMyalo Glen Dlamini
- Derrick KhumaloDKDerrick Khumalo
Open Access
- 10 July 2019
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 1-9
Abstract
Pulmonary tuberculosis is a leading cause of morbidity and mortality in developing countries. Drug resistance, a huge problem in this contagious disease, is driven by point mutations in the Mycobacterium tuberculosis genome however, their frequencies vary geographically and this affects applicability of molecular diagnostics for rapid detection of resistance. Here, we report the frequency and patterns of mutations associated with resistance to second-line anti-TB drugs in multidrug-resistant (MDR) M. tuberculosis isolates from eSwatini, Somalia and Uganda that were resistant to a second-line anti-TB drug. The quinolone resistance determining region (QRDR) of gyrA/gyrB genes and the drug resistance associated fragment of rrs gene from 80 isolates were sequenced and investigated for presence of drug resistance mutations. Of the 80 isolates, 40 were MDR, of which 28 (70%) were resistant to a second-line anti-TB injectable drug, 18 (45%) were levofloxacin resistant while 12 (30%) were extensively drug resistant (XDR). The remaining 40 isolates were susceptible to anti-TB drugs. MIRU-VNTR analysis was performed for M/XDR isolates. We successfully sub-cultured 38 of the 40 M/XDR isolates. The gyrA resistance mutations (Gly88Ala/Cys/Ala, Ala90Val, Ser91Pro, Asp94Gly/Asn) and gyrB resistance mutations (Asp500His, Asn538Asp) were detected in 72.2% (13/18) and 22.2% (4/18) of the MDR and levofloxacin resistant isolates, respectively. Overall, drug resistance mutations in gyrA/gyrB QRDRs occurred in 77.8% (14/18) of the MDR and levofloxacin resistant isolates. Furthermore, drug resistance mutations a1401g and g1484 t in rrs occurred in 64.3% (18/28) of the MDR isolates resistant to a second-line anti-TB injectable drug. Drug resistance mutations were not detected in drug susceptible isolates. The frequency of resistance mutations to second-line anti-TB drugs in MDR-TB isolates resistant to second line anti-TB drugs from eSwatini, Somalia and Uganda is high, implying that rapid molecular tests are useful in detecting second-line anti-TB drug resistance in those countries. Relatedly, the frequency of fluoroquinolone resistance mutations in gyrB/QRDR is high relative to global estimates, and they occurred independently of gyrA/QRDR mutations implying that their absence in panels of molecular tests for detecting fluoroquinolone resistance may yield false negative results in our setting.Keywords
This publication has 41 references indexed in Scilit:
- Anti-Tuberculosis Drug Resistance among New and Previously Treated Sputum Smear-Positive Tuberculosis Patients in Uganda: Results of the First National SurveyPLOS ONE, 2013
- Multidrug-Resistant Tuberculosis, Somalia, 2010–2011Emerging Infectious Diseases, 2013
- New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB MutationsPLOS ONE, 2012
- A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering systemJournal of Antimicrobial Chemotherapy, 2012
- High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009–2010Emerging Infectious Diseases, 2012
- Determination of circulating Mycobacterium tuberculosis strains and transmission patterns among pulmonary TB patients in Kawempe municipality, Uganda, using MIRU-VNTRBMC Research Notes, 2011
- Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugsJournal of Antimicrobial Chemotherapy, 2011
- Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Rates of Anti-Tuberculosis Drug Resistance in Kampala-Uganda Are Low and Not Associated with HIV InfectionPLOS ONE, 2011
- Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national surveyJournal of Antimicrobial Chemotherapy, 2007